Last reviewed · How we verify
PD-1 and CTLA-4 inhibitors
At a glance
| Generic name | PD-1 and CTLA-4 inhibitors |
|---|---|
| Sponsor | Institute of Oncology Ljubljana |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Edema limbs
- Hyperglycemia
- Hypertension
- Alanine aminotransferase increased
- Alkaline phosphatase increased
- Aspartate aminotransferase increased
- Back pain
- Blood bilirubin increased
- Chills
- Cough
- Diarrhea
- Fever
Key clinical trials
- Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors (PHASE1)
- IC Plus Low-dose Radiation Plus Cadonilimab in LANPC (PHASE3)
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG (PHASE1)
- Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer (PHASE2)
- Immune-Related Adverse Events After Cancer Immunotherapy and Safety of Treatment Rechallenge
- IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma (NA)
- Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma (NA)
- Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- PD-1 and CTLA-4 inhibitors CI brief — competitive landscape report
- PD-1 and CTLA-4 inhibitors updates RSS · CI watch RSS
- Institute of Oncology Ljubljana portfolio CI